Immunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis

Background Current treatment regimens for pulmonary tuberculosis require at least 6 months of therapy. Immune adjuvant therapy with recombinant interferon-γ1b (rIFN-γb) may reduce pulmonary inflammation and reduce the period of infectivity by promoting earlier sputum clearance. Methodology/Principal Findings We performed a randomized, controlled clinical trial of directly observed therapy (DOTS) versus DOTS supplemented with nebulized or subcutaneously administered rIFN-γ1b over 4 months to 89 patients with cavitary pulmonary tuberculosis. Bronchoalveolar lavage (BAL) and blood were sampled at 0 and 4 months. There was a significant decline in levels of inflammatory cytokines IL-1β, IL-6, IL-8, and IL-10 in 24-hour BAL supernatants only in the nebulized rIFN-γ1b group from baseline to week 16. Both rIFN-γ1b groups showed significant 3-fold increases in CD4+ lymphocyte response to PPD at 4 weeks. There was a significant (p = 0.03) difference in the rate of clearance of Mtb from the sputum smear at 4 weeks for the nebulized rIFN-γ1b adjuvant group compared to DOTS or DOTS with subcutaneous rIFN-γ1b. In addition, there was significant reduction in the prevalence of fever, wheeze, and night sweats at 4 weeks among patients receiving rFN-γ1b versus DOTS alone. Conclusion Recombinant interferon-γ1b adjuvant therapy plus DOTS in cavitary pulmonary tuberculosis can reduce inflammatory cytokines at the site of disease, improve clearance of Mtb from the sputum, and improve constitutional symptoms. Trial Registration ClinicalTrials.gov NCT00201123

[1]  P. Escalante.  Tuberculosis , 1904, Annals of Internal Medicine.

[2]  M. Perkins,et al.  Confronting the scientific obstacles to global control of tuberculosis. , 2008, The Journal of clinical investigation.

[3]  L. González-Méndez,et al.  Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: A randomized, double-blind, placebo-controlled study , 2008, BMC infectious diseases.

[4]  C. Locht,et al.  Regulatory T cells depress immune responses to protective antigens in active tuberculosis. , 2007, American journal of respiratory and critical care medicine.

[5]  R. Wilkinson,et al.  Neutrophil-mediated innate immune resistance to mycobacteria. , 2007, The Journal of clinical investigation.

[6]  Peter J. Peters,et al.  M. tuberculosis and M. leprae Translocate from the Phagolysosome to the Cytosol in Myeloid Cells , 2007, Cell.

[7]  Alimuddin Zumla,et al.  The stability of mRNA encoding IL-4 is increased in pulmonary tuberculosis, while stability of mRNA encoding the antagonistic splice variant, IL-4delta2, is not. , 2007, Tuberculosis.

[8]  D. Kumararatne,et al.  Disseminated Mycobacterium tuberculosis infection due to interferon γ deficiency. Response to replacement therapy , 2006, Thorax.

[9]  E. Volpe,et al.  Transcriptional profile of the immune response in the lungs of patients with active tuberculosis. , 2006, Clinical immunology.

[10]  V. Deretic,et al.  Autophagy Is a Defense Mechanism Inhibiting BCG and Mycobacterium tuberculosis Survival in Infected Macrophages , 2004, Cell.

[11]  M. Newport,et al.  Clinical features of dominant and recessive interferon γ receptor 1 deficiencies , 2004, The Lancet.

[12]  P. López-Saura,et al.  Adjuvant interferon gamma in patients with drug – resistant pulmonary tuberculosis: a pilot study , 2004, BMC infectious diseases.

[13]  N. Boéchat,et al.  Down-Modulation of Lung Immune Responses by Interleukin-10 and Transforming Growth Factor β (TGF-β) and Analysis of TGF-β Receptors I and II in Active Tuberculosis , 2004, Infection and Immunity.

[14]  W. Rom,et al.  Surfactant Protein A Modulates the Inflammatory Response in Macrophages during Tuberculosis , 2004, Infection and Immunity.

[15]  N. Boéchat,et al.  Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis. , 2004, Infection and immunity.

[16]  E. Chan,et al.  Morphometric analysis of Th(1) and Th(2) cytokine expression in human pulmonary tuberculosis. , 2004, Tuberculosis.

[17]  Gregory A. Taylor,et al.  Immune Control of Tuberculosis by IFN-γ-Inducible LRG-47 , 2003, Science.

[18]  John L. Johnson,et al.  Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[19]  W. Rom,et al.  Recombinant Gamma Interferon Stimulates Signal Transduction and Gene Expression in Alveolar Macrophages In Vitro and in Tuberculosis Patients , 2003, Infection and Immunity.

[20]  R. Chaisson,et al.  Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial , 2002, The Lancet.

[21]  M. D’Elios,et al.  Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo , 2002, European journal of immunology.

[22]  J. Vekemans,et al.  Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-alpha or interleukin-12. , 2001, American journal of respiratory cell and molecular biology.

[23]  Z. Toossi.  The inflammatory response in Mycobacterium tuberculosis infection. , 2000, Archivum immunologiae et therapiae experimentalis.

[24]  Z. Toossi,et al.  Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. , 1999, The Journal of infectious diseases.

[25]  G. Galluccio,et al.  Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. , 1998, American journal of respiratory and critical care medicine.

[26]  W. Rom,et al.  Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol , 1997, The Lancet.

[27]  N. Boéchat,et al.  Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis , 1996, The Journal of experimental medicine.

[28]  W. Rom,et al.  Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis , 1995, Molecular medicine.

[29]  W. Rom,et al.  Enhanced interleukin-8 release and gene expression in macrophages after exposure to Mycobacterium tuberculosis and its components. , 1995, The Journal of clinical investigation.

[30]  J. Flynn,et al.  An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection , 1993, The Journal of experimental medicine.

[31]  J. Vilček,et al.  Mice That Lack the Interferon- 7 Receptor Have Profoundly Altered Responses to Infection with Bacillus Calmette-Gu6rin and Subsequent Ch-ilenge with Lipopolysaccharide By Ryutaro Kamijo,* Junming l.e,* Deborah Shapiro,* , 1993 .

[32]  R. Crystal,et al.  Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-gamma to the human lung. , 1991, The Journal of clinical investigation.